Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls

Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY